The main objective of our study was to systematically evaluate the efficacy and potential influencing factors of PD-1/PD-L1 inhibitors in the treatment of ESCC by comprehensively analyzing data from multiple phase III RCTs. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.